Gourav Roy Choudhury

Dr. Gourav Roy Choudhury

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Neurobiology of Disease
Verified
Journal Article
Closed access
GCGourav Roy Choudhury
Gourav Roy Choudhury
SDShinghua Ding
Shinghua Ding

20 October 2014 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
LXLuokun Xie
Luokun Xie
GCGourav Roy Choudhury
Gourav Roy Choudhury
AWAli Winters
Ali Winters
SYShaohua Yang
Shaohua Yang
KJKunlin Jin
Kunlin Jin
Forkhead box P3 (Foxp3)+ regulatory T (Treg) cells maintain the immune tolerance and prevent inflammatory responses in the periphery. However, the presence of Treg cells in the CNS under steady state has not been studied. Here, for the first time, we show a substantial TCRαβ+CD4+Foxp3+ T‐cell population (cerebral Treg cells) in the rat cerebrum, constituting more than 15% of the cerebral CD4+ T‐cell compartment. Cerebral Treg cells showed an activated/memory phenotype and expressed many Treg‐cell signature genes at higher levels than peripheral Treg cells. Consistent with their activated/memory phenotype, cerebral Treg cells robustly restrained the LPS‐induced inflammatory responses of brain microglia/macrophages, suggesting a role in maintaining the cerebral homeostasis by inhibiting the neuroinflammation. In addition, brain astrocytes were the helper cells that sustained Foxp3 expression in Treg cells through IL‐2/STAT5 signaling, showing that the interaction between astrocytes and Treg cells contributes to the maintenance of Treg‐cell identity in the brain. Taken together, our work represents the first study to characterize the phenotypic and functional features of Treg cells in the rat cerebrum. Our data have provided a novel insight for the contribution of Treg cells to the immunosurveillance and immunomodulation in the cerebrum under steady state.

1 March 2014 in Brain Research
Verified
Journal Article
Closed access
GCGourav Roy Choudhury
Gourav Roy Choudhury
MRMyoung-Gwi Ryou
Myoung-Gwi Ryou
EPEthan Poteet
Ethan Poteet
YWYi Wen
Yi Wen
RHRunlian He
Runlian He
SYShaohua Yang
Shaohua Yang

1 March 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
EPEthan Poteet
Ethan Poteet
GCGourav Roy Choudhury
Gourav Roy Choudhury
AWAli Winters
Ali Winters
WLWenjun Li
Wenjun Li
MRMyoung-Gwi Ryou
Myoung-Gwi Ryou
SYShaohua Yang
Shaohua Yang
Glioblastoma multiforme (GBM), like most cancers, possesses a unique bioenergetic state of aerobic glycolysis known as the Warburg effect. Here, we documented that methylene blue (MB) reverses the Warburg effect evidenced by the increasing of oxygen consumption and reduction of lactate production in GBM cell lines. MB decreases GBM cell proliferation and halts the cell cycle in S phase. Through activation of AMP-activated protein kinase, MB inactivates downstream acetyl-CoA carboxylase and decreases cyclin expression. Structure-activity relationship analysis demonstrated that toluidine blue O, an MB derivative with similar bioenergetic actions, exerts similar action in GBM cell proliferation. In contrast, two other MB derivatives, 2-chlorophenothiazine and promethazine, exert no effect on cellular bioenergetics and do not inhibit GBM cell proliferation. MB inhibits cell proliferation in both temozolomide-sensitive and -insensitive GBM cell lines. In a human GBM xenograft model, a single daily dosage of MB does not activate AMP-activated protein kinase signaling, and no tumor regression was observed. In summary, the current study provides the first in vitro proof of concept that reversal of Warburg effect might be a novel therapy for GBM.

9 October 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ALAi-Ling Lin
Ai-Ling Lin
EPEthan Poteet
Ethan Poteet
FDFang Du
Fang Du
GCGourav Roy Choudhury
Gourav Roy Choudhury
RLRan Liu
Ran Liu
Tim DuongTim Duong
Tim Duong
By restoring mitochondrial function, methylene blue (MB) is an effective neuroprotectant in many neurological disorders (e.g., Parkinson’s and Alzheimer’s diseases). MB has also been proposed as a brain metabolic enhancer because of its action on mitochondrial cytochrome c oxidase. We used in vitro and in vivo approaches to determine how MB affects brain metabolism and hemodynamics. For in vitro, we evaluated the effect of MB on brain mitochondrial function, oxygen consumption, and glucose uptake. For in vivo, we applied neuroimaging and intravenous measurements to determine MB’s effect on glucose uptake, cerebral blood flow (CBF), and cerebral metabolic rate of oxygen (CMRO2) under normoxic and hypoxic conditions in rats. MB significantly increases mitochondrial complex I–III activity in isolated mitochondria and enhances oxygen consumption and glucose uptake in HT-22 cells. Using positron emission tomography and magnetic resonance imaging (MRI), we observed significant increases in brain glucose uptake, CBF, and CMRO2 under both normoxic and hypoxic conditions. Further, MRI revealed that MB dramatically increased CBF in the hippocampus and in the cingulate, motor, and frontoparietal cortices, areas of the brain affected by Alzheimer’s and Parkinson’s diseases. Our results suggest that MB can enhance brain metabolism and hemodynamics, and multimetric neuroimaging systems offer a noninvasive, nondestructive way to evaluate treatment efficacy.

1 August 2015 in Neuroscience
Verified
Journal Article
Closed access
MRM.-G. Ryou
M.-G. Ryou
GCGourav Roy Choudhury
Gourav Roy Choudhury
WLW. Li
W. Li
AWA. Winters
A. Winters
FYF. Yuan
F. Yuan
SYShaohua Yang
Shaohua Yang